Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort
Article first published online: 2 SEP 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 21, Issue 11, pages 1227–1231, November 2012
How to Cite
Purhonen, M., Koponen, H., Tiihonen, J. and Tanskanen, A. (2012), Outcome of patients after market withdrawal of thioridazine: A retrospective analysis in a nationwide cohort. Pharmacoepidem. Drug Safe., 21: 1227–1231. doi: 10.1002/pds.3346
- Issue published online: 29 OCT 2012
- Article first published online: 2 SEP 2012
- Manuscript Accepted: 14 AUG 2012
- Manuscript Revised: 9 AUG 2012
- Manuscript Received: 27 MAR 2012
- drug policy;
- market withdrawal;
- psychotic relapses;
Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. The outcome of clinically stable schizophrenia patients who used thioridazine before market withdrawal was evaluated.
Nationwide registers in Finland were utilized to study thioridazine use, hospitalization rate and length of hospital stay.
Although thioridazine use continued to diminish year after year, the hospitalization rate remained constant until the withdrawal year of 2005, when the percentage of patients hospitalized for schizophrenia doubled.
The market withdrawal of thioridazine predisposed many stable patients towards psychotic relapses. In order to minimize this kind of risk, an overall risk–benefit assessment and a clear-cut plan for the replacement of an antipsychotic should be established before market withdrawal. Copyright © 2012 John Wiley & Sons, Ltd.